{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/allergic-rhinitis/how-up-to-date-is-this-topic/update/","result":{"pageContext":{"chapter":{"id":"7d544db5-f3b7-5709-a2ae-076455d76d20","slug":"update","fullItemName":"Update","depth":2,"htmlHeader":"<!-- begin field a4ef14ea-a1c4-43af-aa2a-b390b91fc207 --><h2>Update</h2><!-- end field a4ef14ea-a1c4-43af-aa2a-b390b91fc207 -->","summary":null,"htmlStringContent":"<!-- begin item 355a8131-56f4-49ee-beae-d9ddb3223d7e --><!-- end item 355a8131-56f4-49ee-beae-d9ddb3223d7e -->","topic":{"id":"e84371ef-9d30-56df-8358-1520fb2c324f","topicId":"0473d89c-2999-40d1-911f-d265b4bd3942","topicName":"Allergic rhinitis","slug":"allergic-rhinitis","lastRevised":"Last revised in September 2018","chapters":[{"id":"5fa28a05-233b-5de6-aee8-ea0327f3c7d6","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"ea1f0c07-a5f8-599b-9b96-71ef8590b2a6","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"99b142c6-9593-51c7-9c86-7c8a537a3b8c","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"67cd9666-b198-574f-9fbf-cd740a7d8c3e","slug":"changes","fullItemName":"Changes"},{"id":"7d544db5-f3b7-5709-a2ae-076455d76d20","slug":"update","fullItemName":"Update"}]},{"id":"392391e3-b09a-5cab-ae2a-040eb039abd9","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"292568d8-a1f5-5b8f-a13d-f3c014fa8e95","slug":"goals","fullItemName":"Goals"},{"id":"2f7129b7-e08b-5e5f-997c-4b661ce0a778","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"8062582a-18e3-58d5-a8cb-f9689e259444","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"1e562233-ae40-5755-abc7-71551f4cea02","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"ccab909c-169d-52aa-ac0a-9d425f89a99c","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"37d61d5d-e2f1-58ef-9c6a-27c4011784f3","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"84432cb8-00ce-599e-9e05-3493755dacd6","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"f59296af-8e0a-509d-b8f3-692efd2bdb92","slug":"definition","fullItemName":"Definition"},{"id":"37020833-afb2-529a-975a-1f1a7a5db2ef","slug":"causes","fullItemName":"Causes"},{"id":"962f75f0-d73d-5c7c-aaf4-d08fc672e6be","slug":"prevalence","fullItemName":"Prevalence"},{"id":"ab993d04-4c7b-59cd-9e56-2e0ef7fdc9db","slug":"complications","fullItemName":"Complications"},{"id":"68b348fd-2864-5da4-8687-6d8c25004f1b","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"80c9e7d3-3315-55b9-98fb-2261b95a1b5c","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"3cc3ef09-2238-5504-8781-48914ad6a4c9","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"5a3f0e38-3f88-5049-beaa-f4cb26499dc6","slug":"assessment","fullItemName":"Assessment"},{"id":"5bd413c7-0398-5b71-acad-a5699c7c703b","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"9b8b1dfa-dfda-5292-a329-64d2c435a006","fullItemName":"Management","slug":"management","subChapters":[{"id":"a132cc60-bb1b-5679-8eda-db080a1e772a","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"760f3c4d-0984-5865-acbe-65d470f66518","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"a47a2aa5-0821-5bf5-987b-2397ac2c982f","slug":"intranasal-antihistamines","fullItemName":"Intranasal antihistamines"},{"id":"449809a3-a714-573e-a21f-8e4295eb984e","slug":"oral-antihistamines","fullItemName":"Oral antihistamines"},{"id":"5507fb81-aa18-5a21-b619-8db3c3c78e80","slug":"intranasal-cromones","fullItemName":"Intranasal cromones"},{"id":"5102b868-dccf-58c1-b6c7-3a59a24c6602","slug":"intranasal-decongestants","fullItemName":"Intranasal decongestants"},{"id":"623ba003-b473-5be2-bc25-e438f1500f7c","slug":"intranasal-anticholinergics","fullItemName":"Intranasal anticholinergics"},{"id":"c871daa0-d649-59f1-b13c-79ab64e7083e","slug":"oral-leukotriene-receptor-antagonists","fullItemName":"Oral leukotriene receptor antagonists"}]},{"id":"f3877d58-da5a-5655-8752-49e87f3a410b","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"87371e7f-8741-54ef-9af6-339f8f0b9285","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"318f5be9-46cf-5fb9-b28c-7ebb4a901904","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"49c3da95-9d4f-5a93-a7ca-e71965fcb981","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"33a2085c-95d6-5004-8f1f-50a08684c638","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"4b1a0d4a-fd5e-5b81-9293-5b2f004871cb","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"735b627c-7d7e-58b8-8196-b4972220342b","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"92889a85-b6e7-58f3-9f09-eae6ca76386c","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"99b142c6-9593-51c7-9c86-7c8a537a3b8c","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"378592e7-a26c-5dbc-bb23-58513a7cab79","slug":"new-evidence","fullItemName":"New evidence","depth":3,"htmlHeader":"<!-- begin field a2fe3311-d08d-4ab0-adb2-90e9c3f821d5 --><h3>New evidence</h3><!-- end field a2fe3311-d08d-4ab0-adb2-90e9c3f821d5 -->","summary":null,"htmlStringContent":"<!-- begin item acadb6ff-af20-438b-b3fb-ccf5dab059e0 --><!-- begin field 940729f9-6650-43a7-8940-ad8b61085bc2 --><h3>Evidence-based guidelines</h3><!-- end field 940729f9-6650-43a7-8940-ad8b61085bc2 --><!-- begin field 2ad3a851-2eb7-4eb9-82f7-8cd345d56ef7 --><p>No new guidelines published since 1 July 2018.</p><!-- end field 2ad3a851-2eb7-4eb9-82f7-8cd345d56ef7 --><!-- begin field 661842fe-02dd-4dc8-a1c6-06a106c1b490 --><h3>HTAs (Health Technology Assessments)</h3><!-- end field 661842fe-02dd-4dc8-a1c6-06a106c1b490 --><!-- begin field 335ccf69-48bf-4061-b12a-ec06cf10659c --><p>No new HTAs since 1 July 2018.</p><!-- end field 335ccf69-48bf-4061-b12a-ec06cf10659c --><!-- begin field 51922930-131e-4c09-8217-a0ca67faa73e --><h3>Economic appraisals</h3><!-- end field 51922930-131e-4c09-8217-a0ca67faa73e --><!-- begin field be2ed1aa-7694-4aa6-b3f8-ac1367271d3e --><p>No new economic appraisals relevant to England since 1 July 2018.</p><!-- end field be2ed1aa-7694-4aa6-b3f8-ac1367271d3e --><!-- begin field eab585f2-8a0f-4349-a987-3ffcb09e5951 --><h3>Systematic reviews and meta-analyses</h3><!-- end field eab585f2-8a0f-4349-a987-3ffcb09e5951 --><!-- begin field d51f86cd-1734-477e-a884-fdb0462a8b36 --><p>No new systematic reviews published since 1 July 2018.</p><!-- end field d51f86cd-1734-477e-a884-fdb0462a8b36 --><!-- begin field 7d2743e0-0101-430e-aabc-18cc527c4d42 --><h3>Primary evidence</h3><!-- end field 7d2743e0-0101-430e-aabc-18cc527c4d42 --><!-- begin field 8991334f-be4b-46ad-a844-08a5b9adea79 --><p>No new randomized controlled trials published since 1 July 2018.</p><!-- end field 8991334f-be4b-46ad-a844-08a5b9adea79 --><!-- end item acadb6ff-af20-438b-b3fb-ccf5dab059e0 -->","subChapters":[]},{"id":"9cd9727c-ab6e-59b0-9e37-b3f7d3a79d4a","slug":"new-policies","fullItemName":"New policies","depth":3,"htmlHeader":"<!-- begin field c3e3506b-63da-4601-96a9-5940dd378ab3 --><h3>New policies</h3><!-- end field c3e3506b-63da-4601-96a9-5940dd378ab3 -->","summary":null,"htmlStringContent":"<!-- begin item 27bec704-4a1b-4b4a-9189-d33d67306f20 --><!-- begin field 2676618b-a5b3-4617-b5b8-4c3383f244db --><p>No new national policies or guidelines since 1 July 2018.</p><!-- end field 2676618b-a5b3-4617-b5b8-4c3383f244db --><!-- end item 27bec704-4a1b-4b4a-9189-d33d67306f20 -->","subChapters":[]},{"id":"bbba7e33-d8c4-53d3-820b-b7597c157636","slug":"new-safety-alerts","fullItemName":"New safety alerts","depth":3,"htmlHeader":"<!-- begin field 0ef27b32-5c54-4fa6-9cf1-7ed233187ead --><h3>New safety alerts</h3><!-- end field 0ef27b32-5c54-4fa6-9cf1-7ed233187ead -->","summary":null,"htmlStringContent":"<!-- begin item 9c7a91a0-f67f-4d98-99cd-34bf2c8cd53f --><!-- begin field 79b787d7-c393-4d56-a40f-a7472a56f613 --><p>No new safety alerts since 1 July 2018.</p><!-- end field 79b787d7-c393-4d56-a40f-a7472a56f613 --><!-- end item 9c7a91a0-f67f-4d98-99cd-34bf2c8cd53f -->","subChapters":[]},{"id":"681a778f-eb16-554b-b74d-542a5be48915","slug":"changes-in-product-availability","fullItemName":"Changes in product availability","depth":3,"htmlHeader":"<!-- begin field 4a6ff046-a72c-42e2-80e8-e2cc911087dc --><h3>Changes in product availability</h3><!-- end field 4a6ff046-a72c-42e2-80e8-e2cc911087dc -->","summary":null,"htmlStringContent":"<!-- begin item aa9b427f-c367-405a-ba20-df315745281b --><!-- begin field 56878717-50df-42e7-9a8a-a383682b8ff5 --><ul><li>Bilastine 10 mg orodispersible tablets are non-sedating, long-acting histamine antagonist with selective peripheral H1 receptor antagonist affinity are licensed for use in children aged 6 to 11 years with body weight ≥20 kg for symptomatic treatment of allergic rhino-conjunctivitis (seasonal, perennial) and urticaria. See more <a href=\"https://www.medicines.org.uk/emc/product/11727/smpc\" data-hyperlink-id=\"ba219d52-3bfd-4101-80a0-ac4f00a721d8\">here</a>.</li><li>Bilastine 2.5 mg/mL oral solution is licensed for the symptomatic treatment of rhino-conjunctivitis (seasonal and perennial) in children aged 6 to 11 years with a body weight of at least 20 kg. See more <a href=\"https://www.medicines.org.uk/emc/product/11725/smpc\" data-hyperlink-id=\"4b645e81-4086-432e-9a43-ac7500ffdebc\">here</a>.</li></ul><!-- end field 56878717-50df-42e7-9a8a-a383682b8ff5 --><!-- end item aa9b427f-c367-405a-ba20-df315745281b -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}